4 Results for "

70024-40-7

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "70024-40-7" in MCE Product Catalog:

8
8 Publications Verification
Cat. No.: HY-B0371A
CAS No.: 70024-40-7
Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
loading...
    loading...
Cat. No.: HY-B0371AR
CAS No.: 70024-40-7
Terazosin (hydrochloride dihydrate) (Standard) is the analytical standard of Terazosin (hydrochloride dihydrate). This product is intended for research and analytical applications. Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
loading...
    loading...
8
8 Publications Verification
Cat. No.: HY-B0371F
CAS No.: 63074-08-8
Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
loading...
    loading...
8
8 Publications Verification
Cat. No.: HY-B0371
CAS No.: 63590-64-7
Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
loading...
    loading...